Evidence map›Paper›PMID 41461923›Full record

ReviewMolecular psychiatry2026

Rapid antidepressant potential of nitrous oxide: current state and major questions.

Charles F Zorumski, Joseph Cichon, Yukitoshi Izumi, Thomas Zeffiro, Steven Mennerick, Peter Nagele, Charles R Conway

Abstract readReview
In one paragraph

Review in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Charles F ZorumskiDepartment of Psychiatry and the Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA. zorumskc@wustl.edu.ORCID http://orcid.org/0000-0002-9704-5154
Joseph CichonDepartment of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Yukitoshi IzumiDepartment of Psychiatry and the Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-5596-1031
Thomas ZeffiroDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0846-4577
Steven MennerickDepartment of Psychiatry and the Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-0868-0664
Peter NageleDepartment of Anesthesia and Critical Care, University of Chicago School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-8369-3858
Charles R ConwayDepartment of Psychiatry and the Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA.

Funding

Neuroactive steroids as novel psychiatric treatments: mechanistic studiesP50MH122379 · NIMH · WASHINGTON UNIVERSITY · PI MENNERICK, STEVEN J · 2021 to 2025
$12.2M
GABAA RECEPTOR POPULATIONS IN HIPPOCAMPUS AND THALAMUSR01MH123748 · NIMH · WASHINGTON UNIVERSITY · PI MENNERICK, STEVEN J · 2021 to 2025
$2.4M
Cellular and circuit mechanisms of the therapeutic action of inhaled nitrous oxide in rodent models of chronic stressR35GM151160 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI JOSEPH CICHON · 2023 to 2026
$1.7M
NIGMS NIH HHS R35 GM151160NIMH NIH HHS P50 MH122379NIMH NIH HHS R01 MH123748U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM151160-01U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH101874U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH108901U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH122379U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH123748
6 · The paper itself

Abstract

The success of ketamine, a dissociative anesthetic and non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, as a rapidly acting antidepressant has ignited efforts to identify other novel depression treatments. In recent years, several clinical trials indicated that nitrous oxide (N

Indexed as

Antidepressive AgentsNitrous OxideAnimalsBrainDepressive Disorder, Treatment-ResistantHumansKetamineMajor Depressive DisorderReceptors, N-Methyl-D-AspartateAntidepressive AgentsKetamineNitrous OxideReceptors, N-Methyl-D-Aspartate

Identifiers

PMID41461923
PMCPMC13190246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.